Atsena Therapeutics Granted U.S. FDA Regenerative Medicine Advanced Therapy Designation for ATSN-201 Gene Therapy To Treat X-Linked Retinoschisis
UF startup Atsena Therapeutics announced that the U.S. FDA has granted Regenerative Medicine Advanced Therapy designation for ATSN-201 for the treatment of X-linked retinoschisis.
Oragenics, Inc. Announces Health and Disability Ethics Committee Submission for Phase IIa Concussion Trial
UF Innovate | Accelerate graduate Oragenics announced that it has submitted a clinical trial protocol for regulatory review to the Health and Disability Ethics Committee (HDEC) in New Zealand.
LightPath Technologies Awarded Initial $2.2 Million IR Camera Order for U.S. Navy Shipboard Optics (SPEIR) Program
UF startup LightPath Technologies announced its acquired subsidiary G5 Infrared has been awarded an initial $2.2 million engineering development model (EDM) order for infrared cameras by L3Harris Technologies.
Rise Therapeutics Reports Ulcerative Colitis Dose Escalation Clinical Results for R-3750 at the Digestive Disease Week (DDW) Conference in San Diego May 3–6
UF startup Rise Therapeutics announced that it will report its first clinical results from the completed dose escalation segment of its R-3750 Phase 1 clinical trial in ulcerative colitis at the upcoming DDW conference.
Atsena Therapeutics Announces Oversubscribed $150 Million Series C Financing To Further Advance Ocular Gene Therapy Programs
UF startup Atsena Therapeutics, a clinical-stage gene therapy company focused on reversing or preventing blindness, announced the successful close of an oversubscribed $150 million Series C financing round.
LightPath Technologies Secures $4.8 Million Qualification Order for Infrared Cameras With New Defense Customer
UF startup LightPath Technologies, Inc. announced that its recently acquired subsidiary G5 Infrared received a $4.8 million initial qualification order for infrared cameras from a new defense industry customer.
Scripps Institute Spin-Out Company Raises $3 Million
UF startup Myosin Therapeutics, a biotechnology company developing medications to treat brain cancer and methamphetamine addiction, secured $3 million in seed funding.
JAMA Neurology Publishes Landmark Study Showing Neuropacs™ AI Technology Significantly Enhances the Diagnostic Accuracy of Parkinson’s Disease and Atypical Parkinsonism
UF startup neuropacs™ Corp., a leading innovator in AI-driven neurological diagnostics, announces the results of a prospective multicenter study that evaluated neuropacs™ AI technology for diagnosing Parkinson’s disease and atypical parkinsonism.
iOncologi, Inc. Acquires TargImmune Therapeutics To Expand and Strengthen Immunotherapy Pipeline Against Solid Tumors
UF startup iOncologi announced the acquisition of TargImmune Therapeutics to enhance its capabilities in developing immunotherapies for solid tumors.
Atsena Therapeutics Granted U.S. FDA Fast Track Designation for ATSN-201 Gene Therapy To Treat X-Linked Retinoschisis
UF startup Atsena Therapeutics announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for ATSN-201 for the treatment of X-linked retinoschisis (XLRS).
